Our previous studies have revealed that the non-toxic dose (> 90% survival) of PARP inhibitors was 15 μM for rucaparib, olaparib and veliparib, and 1.25 μM for talazoparib in A549 NSCLC cells (21). Here, PARP1 is linked to non-small cell lung carcinoma.